Joinn Laboratories: Revenue of 1.188 billion yuan in the first three quarters, net profit up 1051.94% year on year.

JOINN Laboratories announced that in the third quarter of 2026, it achieved operating revenue of 484 million yuan, a year-on-year increase of 53.01%; net profit attributable to the parent company of 182 million yuan, a year-on-year increase of 821.27%; net profit attributable to the parent company after deducting non-recurring gains and losses of 182 million yuan, a year-on-year increase of 2,938.46%. In the first three quarters of 2026, it achieved operating revenue of 1.188 billion yuan, a year-on-year increase of 20.60%; net profit attributable to the parent company of 930 million yuan, a year-on-year increase of 1,051.94%; net profit attributable to the parent company after deducting non-recurring gains and losses of 881 million yuan, a year-on-year increase of 2,933.08%. The performance growth was mainly due to the combined impact of an increase in gross profit and gains from changes in the fair value of biological assets. In the first three quarters, cumulative newly signed orders amounted to 3.42 billion yuan, a year-on-year increase of 109%; as of the end of the reporting period, orders on hand were 4.5 billion yuan, a year-on-year increase of 80%.